Idera Pharmaceuticals, Inc. (IDRA) Reports Third Quarter 2009 Financial Results and Provides Pipeline Update
11/5/2009 9:16:30 AM
More...
|
Idera Pharmaceuticals, Inc. (IDRA) Presents Preclinical Data on IMO-2125, its Lead Drug Candidate for Chronic Hepatitis C Virus Infection, at Liver Meeting 2009
11/3/2009 9:32:11 AM
More...
|
Idera Pharmaceuticals, Inc. (IDRA) Announces Issuance of Patents Covering its Novel Toll-like Receptor-Targeted Compounds and Their Use
10/26/2009 9:13:07 AM
More...
|
Idera Pharmaceuticals, Inc. (IDRA) Presents Preclinical Data at ACR/ARHP 2009 Annual Meeting on IMO-3100, a Toll-Like Receptor Antagonist, in Combination with Enbrel(R) in Arthritis Model
10/19/2009 8:33:31 AM
More...
|
Idera Pharmaceuticals, Inc. (IDRA) to Present at 8th Annual Biotechnology Industry Organization (BIO) Investor Forum
10/16/2009 8:08:43 AM
More...
|
Idera Pharmaceuticals, Inc. (IDRA) Initiates Phase 1 Clinical Trial of IMO-2125, a TLR9 Agonist, in Combination with Ribavirin for Chronic Hepatitis C Virus Infection
10/7/2009 8:08:07 AM
More...
|
Idera Pharmaceuticals, Inc. (IDRA) to Present at 11th Annual Massachusetts Biotechnology Investors Forum
10/1/2009 9:35:27 AM
More...
|
Idera Pharmaceuticals, Inc. (IDRA) Presents Final Data from Phase 2 Clinical Trial of IMO-2055 Monotherapy in Renal Cell Carcinoma
9/25/2009 8:32:52 AM
More...
|
Idera Pharmaceuticals, Inc. (IDRA) Presents Interim Data from Phase 1b Clinical Trial of IMO-2055 in Combination with Tarceva(R) and Avastin(R) in Non-Small Cell Lung Cancer
9/23/2009 9:10:57 AM
More...
|
Idera Pharmaceuticals, Inc. (IDRA) to Present at UBS Global Life Sciences Conference
9/15/2009 9:31:56 AM
More...
|
|